Inkontan

Trospium Chloride, the active ingredient in Inkontan, is an antimuscarinic (anticholinergic) presented as an oral tablet for systemic use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency, nocturia and urge urinary incontinence in adult patients.

GNH USA supplies Inkontan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inkontan (trospium chloride) is used to treat conditions related to detrusor overactivity within the lower urinary tract.

- Overactive bladder: reduces urgency episodes and improves bladder capacity. - Urge urinary incontinence: decreases the number of incontinence episodes. - Urinary frequency: lowers daytime voiding frequency. - Nocturia: diminishes nighttime awakenings to void.

Trospium chloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth: reduced salivary secretion leading to a feeling of thirst. - Constipation: slowed gastrointestinal motility. - Blurred vision: transient visual disturbances. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Acute urinary retention: inability to void requiring medical intervention. - Angle‑closure glaucoma: sudden eye pain and visual loss. - Cardiac arrhythmia: irregular heart rhythm, especially in susceptible patients.

Before initiating therapy with Inkontan, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution; monitor liver enzymes. - Narrow‑angle glaucoma: avoid use in patients with this condition. - Elderly patients: monitor for anticholinergic burden and cognitive effects. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Trospium chloride can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase trospium plasma concentrations. - P‑glycoprotein inhibitors: can raise systemic exposure. - Other anticholinergic agents: additive anticholinergic effects may occur.

Moderate Interactions (Monitor Closely): - Diuretics: may alter urinary symptoms. - Antihistamines: increase risk of dry mouth and constipation. - Beta‑agonists: potential for increased heart rate and palpitations.